Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include 32 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

Take charge of your eye health!

Making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. we encourage everyone to take charge of their eye health and preserve their sight by following some simple tips.

Click here for more!

Latest News From RCA

Dr. Mark Barakat’s ASRS 2020 Virtual Presentation

This year at the virtual American Society of Retinal Specialists (ASRS) convention, Dr. Mark Barakat gave an update on the Kodiak trial, currently ongoing at the Retinal Research Institute. Watch one of “ASRS Tops Sessions to Watch” by Ophthalmology 360.

Dr. Mark Barakat’s Virtual ASRS Interview with Nick Steinle, MD

Watch Dr. Mark R. Barakat be interviewed by Nick Steinle, MD from California Retina Consultants following his presentation at the virtual 2020 ASRS convention. In his presentation, Dr. Barakat discusses the Kodiac trials currently undergoing at the Retinal Research Institute.

Pravin U. Dugel MD: Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial

CINCINNATI–(BUSINESS WIRE)– Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients… Read More »